Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Po-Lan Su

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
JTO Clinical and Research Reports|March 7, 2022
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE StudyPo-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 18, 2021
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysisJeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, et al.
World Journal of Surgical Oncology|November 25, 2023
Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patientsPang-Shuo Perng, Heng-Juei Hsu, Jung-Shun Lee, et al.
Thoracic Cancer|November 20, 2021
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitorsSheng-Yuan Wang, Ching-Han Lai, Chian-Wei Chen, et al.
Cancer Medicine|August 22, 2019
Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatmentPo-Lan Su, Szu-Chun Yang, Yi-Lin Chen, et al.
Scientific Reports|March 30, 2021
Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapyHsien-Yuan Chang, Chun-Hui Lee, Po-Lan Su, et al.
Biosensors & Bioelectronics|September 10, 2023
Single-sized N-functionality graphene quantum dot in tunable dual-modality near infrared-I/II illumination detection and photodynamic therapy under multiphoton nonlinear excitationWen-Shuo Kuo, Chia-Yuan Chang, Hao-Yu Chuang, et al.
Thoracic Cancer|May 15, 2023
Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort studyChien-Yu Lin, Chia-Hao Hu, Chia-Fu Hsu, et al.
Biosensors & Bioelectronics|December 4, 2023
Corrigendum to "Single-sized N-functionality graphene quantum dot in tunable dual-modality near infrared-I/II illumination detection and photodynamic therapy under multiphoton nonlinear excitation" [Biosens. Bioelectron. 241 (2023) 115648/ DOI: 10.1016/j.bios.2023.115648]Wen-Shuo Kuo, Chia-Yuan Chang, Hao-Yu Chuang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2021
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatmentPo-Lan Su, Jeng-Shiuan Tsai, Szu-Chun Yang, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
JTO Clinical and Research Reports|March 7, 2022
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE StudyPo-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 18, 2021
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysisJeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, et al.
World Journal of Surgical Oncology|November 25, 2023
Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patientsPang-Shuo Perng, Heng-Juei Hsu, Jung-Shun Lee, et al.
Thoracic Cancer|November 20, 2021
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitorsSheng-Yuan Wang, Ching-Han Lai, Chian-Wei Chen, et al.
Cancer Medicine|August 22, 2019
Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatmentPo-Lan Su, Szu-Chun Yang, Yi-Lin Chen, et al.
Scientific Reports|March 30, 2021
Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapyHsien-Yuan Chang, Chun-Hui Lee, Po-Lan Su, et al.
Biosensors & Bioelectronics|September 10, 2023
Single-sized N-functionality graphene quantum dot in tunable dual-modality near infrared-I/II illumination detection and photodynamic therapy under multiphoton nonlinear excitationWen-Shuo Kuo, Chia-Yuan Chang, Hao-Yu Chuang, et al.
Thoracic Cancer|May 15, 2023
Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort studyChien-Yu Lin, Chia-Hao Hu, Chia-Fu Hsu, et al.
Biosensors & Bioelectronics|December 4, 2023
Corrigendum to "Single-sized N-functionality graphene quantum dot in tunable dual-modality near infrared-I/II illumination detection and photodynamic therapy under multiphoton nonlinear excitation" [Biosens. Bioelectron. 241 (2023) 115648/ DOI: 10.1016/j.bios.2023.115648]Wen-Shuo Kuo, Chia-Yuan Chang, Hao-Yu Chuang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2021
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatmentPo-Lan Su, Jeng-Shiuan Tsai, Szu-Chun Yang, et al.
Pageof 7